13,157 results on '"Genentech Inc."'
Search Results
2. 3 Things You Should Know About the Latest in nAMD and DME Treatment
3. Study Data from Genentech Inc. Provide New Insights into Age-Related Macular Degeneration (SLC16A8 is a causal contributor to age-related macular degeneration risk)
4. Researchers from Genentech Inc. Describe Findings in Biotechnology (Multiplexed, Image-based Pooled Screens In Primary Cells and Tissues With Perturbview)
5. Researchers at Genentech Inc. Zero in on Science [Overloading And unpacKing (OAK) - droplet-based combinatorial indexing for ultra-high throughput single-cell multiomic profiling]
6. New Engineered Antibodies Study Results from Genentech Inc. Described (Immunogenicity Risk Assessment and Mitigation for Engineered Antibody and Protein Therapeutics)
7. New Organ Preservation Study Findings Have Been Reported from Genentech Inc. (Drug Development Considerations for Additives to Organ Preservation Solutions)
8. Foundation Medicine reports FDA approval of FoundationOneLiquid CDx as companion diagnostic for Itovebi
9. Positive Phase III Results Show Xofluza Significantly Reduces the Transmission of Influenza Viruses
10. Researchers at Genentech Inc. Publish New Data on Melanoma (Computational Modeling of Drug Response Identifies Mutant-Specific Constraints for Dosing panRAF and MEK Inhibitors in Melanoma)
11. Reports Summarize Engineered T-Cells Research from Genentech Inc. (Assessing a single-cell multi-omic analytic platform to characterize ex vivo-engineered T-cell therapy products)
12. Genentech reports positive Phase I Results for oral GLP-1 agonist CT-996
13. Genentech gains FDA approval for Vabysmo prefilled syringe in treating causes of vision loss
14. Genentech ends trial as combination therapy fails to meet efficacy endpoints in lung cancer
15. Studies from Genentech Inc. Provide New Data on Ulcerative Colitis (Gut microbial species and endotypes associate with remission in ulcerative colitis patients treated with anti-TNF or anti-integrin therapy)
16. New Ophthalmic Preparations Data Have Been Reported by Investigators at Genentech Inc. (Impact of P-gp Inhibition On Systemic Exposure of Pralsetinib and Dosing Considerations)
17. Studies from Genentech Inc. Yield New Data on Antiarrhythmic Agents (Introducing the Dynamic Well-stirred Model for Predicting Hepatic Clearance and Extraction Ratio)
18. Research on Pharmaceutics Described by Researchers at Genentech Inc. (A Minimal PBPK/PD Model with Expansion-Enhanced Target-Mediated Drug Disposition to Support a First-in-Human Clinical Study Design for a FLT3L-Fc Molecule)
19. Q2 2024 Nykode Therapeutics ASA Earnings Call - Final
20. FDA grants Breakthrough Therapy Designation to Genentech's inavolisib for advanced breast cancer
21. Findings from Genentech Inc. Has Provided New Data on Immunoglobulins (Implementation of a Three-way Comparability Assessment for a Bioanalytical Anti-drug Antibody Method)
22. Study Findings on Graft-Versus-Host Disease Are Outlined in Reports from Genentech Inc. (Clinical Pharmacology Considerations for the 'off-the-shelf' Allogeneic Cell Therapies)
23. Deep learning model for AI: Stopping nascent GA in its tracks: Researchers found the model demonstrated 'near-perfect' detection capabilities
24. New Findings from Genentech Inc. in Gram-Negative Bacteria Provides New Insights (Inhibitors Targeting Bama In Gram-negative Bacteria)
25. New Colitis Findings Has Been Reported by Investigators at Genentech Inc. (An Agonistic Anti-signal Regulatory Protein a Antibody for Chronic Inflammatory Diseases)
26. Researchers' Work from Genentech Inc. Focuses on Drug Conjugates (Automated Online Deconjugation of Antibody-drug Conjugate for Small Molecule Drug Profiling)
27. 10-Q: LINEAGE CELL THERAPEUTICS, INC
28. 10-Q: CURIS INC
29. 10-Q: ADAPTIMMUNE THERAPEUTICS PLC
30. 8-K: SANGAMO THERAPEUTICS, INC
31. 10-Q: SANGAMO THERAPEUTICS, INC
32. New England Journal of Medicine Publishes Landmark Phase III Results for Genentech's Itovebi, Showing More Than Doubling of Progression-Free Survival in Certain Type of HR-Positive Advanced Breast Cancer
33. Neuvivo Expands Board of Directors in Preparation of Upcoming NDA Review with the Appointment of Robert Baffi, PhD, MBA
34. Genentech's Vabysmo Improved Vision in Underrepresented Populations With Diabetic Macular Edema (DME) in a First-Of-Its-Kind Study
35. Genentech's Vabysmo Improved Vision in Underrepresented Populations with Diabetic Macular Edema in a First-Of-Its-Kind Study
36. Genentech's Vabysmo Improved Vision in Underrepresented Populations With Diabetic Macular Edema (DME) in a First-Of-Its-Kind Study
37. Johns Hopkins - Immune Signatures May Predict Adverse Events in Patients Taking Immunotherapy
38. Majority of Children With Spinal Muscular Atrophy (SMA) Treated With Genentech's Evrysdi Are Able to Sit, Stand and Walk Independently, Two-Year Data Demonstrate
39. Majority of Children With Spinal Muscular Atrophy (SMA) Treated With Genentech's Evrysdi Are Able to Sit, Stand and Walk Independently, Two-Year Data Demonstrate
40. FDA Approves Genentech's Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
41. Positive Phase III Results for Genentech's Gazyva Show Superiority to Standard Therapy Alone in People With Lupus Nephritis
42. 8-K: Adaptimmune Therapeutics PLC
43. Positive Phase III Results Show Xofluza Significantly Reduces the Transmission of Influenza Viruses
44. FDA Approves Ocrevus Zunovo[TM] as the First and Only Twice-a-Year 10-Minute Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis
45. FDA Approves Genentech's Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy
46. Data on Biotechnology Reported by Researchers at Genentech Inc. (Ugt1a4 Polymorphism Is Not Associated With a Clinically Relevant Change In Giredestrant Exposure)
47. New Monoclonal Antibodies Study Findings Have Been Reported by Investigators at Genentech Inc. (Reducing Immunogenicity By Design: Approaches To Minimize Immunogenicity of Monoclonal Antibodies)
48. Data on Antibody Engineering Published by Researchers at Genentech Inc. (i-shaped antibody engineering enables conformational tuning of biotherapeutic receptor agonists)
49. Genentech enhances biologics manufacturing with C3 AI's predictive maintenance
50. Genentech enhances biologics manufacturing with C3 AI's predictive maintenance
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.